Attached files

file filename
8-K - FORM 8-K - ALBEMARLE CORPd335862d8k.htm

Exhibit 99.1

 

LOGO  

Contact:

Lorin Crenshaw            225.388.7322

Albemarle Reports Growth In First Quarter 2012 Results

 

 

BATON ROUGE, LA - April 18, 2012 –

First quarter 2012 highlights:

 

   

Quarterly net sales of $712 million and earnings of $1.20 per share both of which were up over prior year.

 

   

EBITDA of $176 million and EBITDA margin of 25 percent for the quarter.

 

     Three Months Ended  
     March 31,  

In thousands, except per share amounts

   2012      2011  

Net sales

   $ 711,704       $ 696,530   

Segment income

   $ 174,263       $ 171,600   

Net income attributable to Albemarle Corporation

   $ 108,043       $ 106,580   

Diluted earnings per share

   $ 1.20       $ 1.15   

Albemarle Corporation (NYSE: ALB) reported first quarter 2012 earnings of $108.0 million, or $1.20 per share, compared to first quarter 2011 earnings of $106.6 million, or $1.15 per share. The Company reported net sales of $711.7 million in the first quarter of 2012 compared to net sales of $696.5 million in the first quarter of 2011.

“I am pleased to announce first quarter results that reflect an excellent start to 2012. Year over year earnings growth in Catalysts and Fine Chemistry points to continued strong trends in those businesses, while a sequential rebound in Polymer Solutions appears to signal the early stages of a recovery, the breadth and vigor of which remains to be seen,” said Luke Kissam, CEO. “Assuming the global economic recovery continues and strengthens in the second half of the year, we continue to expect to grow our business for the full year and make further progress toward the goals we outlined in Vision 2015.”

 

1


Quarterly Segment Results

Catalysts generated net sales of $293.5 million in the first quarter of 2012, a 12 percent increase over net sales in the first quarter of 2011, due mainly to favorable pricing. Catalysts segment income was $82.2 million in the first quarter of 2012, up 13 percent over first quarter 2011 results of $72.6 million due primarily to favorable pricing partly offset mainly by higher input costs and lower equity income versus the first quarter of 2011.

Polymer Solutions delivered net sales of $228.1 million in the first quarter of 2012, a 12 percent decrease over net sales in the first quarter of 2011, with favorable impacts from pricing being offset overall by lower volumes. Segment income for Polymer Solutions was $53.6 million in the first quarter of 2012, a 23 percent decline from $69.5 million in the first quarter of 2011, due primarily to lower volumes as well as lower equity income, partly offset by favorable pricing and lower charges attributable to the noncontrolling interest in our Jordanian joint venture.

Fine Chemistry net sales in the first quarter of 2012 were $190.1 million, a 7 percent increase over net sales in the first quarter of 2011, due mainly to favorable pricing and volumes. Segment income for Fine Chemistry was $38.6 million for the first quarter of 2012, over 30 percent higher than first quarter 2011 results of $29.5 million, due primarily to favorable pricing and volume performance and lower charges attributable to the noncontrolling interest in our Jordanian joint venture, partly offset by higher input costs.

Corporate and Other

Corporate and other expense was $21.9 million for the first quarter of 2012. The decrease over the comparable period in 2011 was due primarily to lower personnel-related costs including performance-based incentive compensation.

Interest and financing expenses were $8.7 million for the first quarter of 2012 compared to $9.6 million for the first quarter of 2011, with this decrease due primarily to increases in interest capitalized on higher average construction project balances outstanding year over year.

Our first quarter 2012 effective income tax rate was 25.5 percent versus 24.2 percent in the first quarter of 2011. Our effective tax rate continues to be influenced by the level and geographic mix of income and benefits from a favorable mix of income in lower tax jurisdictions.

 

2


Cash Flow

Our cash flow from operations was approximately $124 million for the three months ended March 31, 2012, and we had $519.4 million in cash and cash equivalents at March 31, 2012. During the three months ended March 31, 2012, cash on hand and cash provided by operations funded capital expenditures for plant, machinery and equipment of approximately $54.8 million (which includes approximately $18.3 million in capital expenditures associated with our Jordan Bromine joint venture), long-term debt repayments of $7.1 million and dividends to shareholders of $15.6 million.

Outlook

Although uncertainty persists regarding the strength and duration of a global economic recovery, the full year outlook for Catalysts and Fine Chemistry remains favorable, supported by positive industry trends and new business opportunities. In Polymer Solutions, end-market patterns suggest a continuation of the recent gradual demand build through the second half of 2012. Overall, our businesses remain fundamentally healthy and strategically well-positioned.

Earnings Call

The Company’s performance for the first quarter ended March 31, 2012 will be discussed on a conference call at 8:00 AM Eastern Daylight time on April 19, 2012. The call can be accessed by dialing 866-831-6247 (International Dial In # 617-213-8856), and entering conference ID 37921496. The Company’s earnings presentation and supporting material can be accessed through Albemarle’s website under Investors at www.albemarle.com.

About Albemarle

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services. Albemarle is committed to global sustainability and is advancing its eco-practices and solutions in its three business segments, Polymer Solutions, Catalysts and Fine Chemistry, with Corporate Responsibility Magazine naming Albemarle among its prestigious “100 Best Corporate Citizens” list for 2011. Albemarle employs more than 4,000 people worldwide and serves customers in approximately 100 countries. Albemarle regularly posts information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, Regulation G reconciliations, SEC filings and other information regarding the Company, its businesses and markets served.

Forward-Looking Statements

Some of the information presented in this press release, including, without limitation, statements with respect to product development, improvements in productivity, market trends, price and mix changes, expected growth, outlook and all other information relating to matters that are not historical facts may constitute forward-looking

 

3


statements within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially. Factors that could cause actual results to differ from expectations include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; changes in the cost of raw materials and energy and in our ability to pass through increases; acquisitions and divestitures, and changes in performance of acquired companies; fluctuations in foreign currencies; changes in laws and government regulation of our operations or our products; the occurrence of claims or litigation; the occurrence of natural disasters; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest, including terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings; changes in monetary policies or inflation or interest rates, which may impact our ability to raise capital or increase our cost of funds, the performance of our pension fund investments and our pension expense and funding obligations; volatility and substantial uncertainties in the debt and equity markets; technology or intellectual property infringement and other risks; decisions we may make in the future; and the other factors detailed from time to time in the reports we file with the SEC, including those described under “Risk Factors” in our Annual Report on Form 10-K.

 

4


Albemarle Corporation and Subsidiaries

Consolidated Statements of Income

(In Thousands Except Per Share Amounts) (Unaudited)

 

     Three Months Ended
March 31,
 
     2012     2011  

Net sales

   $ 711,704      $ 696,530   

Cost of goods sold

     463,817        463,514   
  

 

 

   

 

 

 

Gross profit

     247,887        233,016   

Selling, general and administrative expenses (a)

     80,692        73,039   

Research and development expenses

     19,049        17,615   
  

 

 

   

 

 

 

Operating profit

     148,146        142,362   

Interest and financing expenses

     (8,734     (9,592

Other (expenses) income, net

     (118     338   
  

 

 

   

 

 

 

Income before income taxes and equity in net income of unconsolidated investments

     139,294        133,108   

Income tax expense

     35,466        32,172   
  

 

 

   

 

 

 

Income before equity in net income of unconsolidated investments

     103,828        100,936   

Equity in net income of unconsolidated investments (net of tax)

     8,586        12,831   
  

 

 

   

 

 

 

Net income

     112,414        113,767   

Net income attributable to noncontrolling interests

     (4,371     (7,187
  

 

 

   

 

 

 

Net income attributable to Albemarle Corporation

   $ 108,043      $ 106,580   
  

 

 

   

 

 

 

Basic earnings per share

   $ 1.21      $ 1.16   

Diluted earnings per share

   $ 1.20      $ 1.15   

Weighted-average common shares outstanding – Basic

     88,997        91,633   

Weighted-average common shares outstanding – Diluted

     89,947        92,517   

See accompanying notes to the condensed consolidated financial information.

 

5


Albemarle Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands) (Unaudited)

 

     March 31,      December 31,  
     2012      2011  

ASSETS

     

Cash and cash equivalents

   $ 519,359       $ 469,416   

Other current assets

     950,197         886,204   
  

 

 

    

 

 

 

Total current assets

     1,469,556         1,355,620   
  

 

 

    

 

 

 

Property, plant and equipment

     2,681,153         2,619,428   

Less accumulated depreciation and amortization

     1,513,931         1,489,948   
  

 

 

    

 

 

 

Net property, plant and equipment

     1,167,222         1,129,480   

Other assets and intangibles

     726,721         718,724   
  

 

 

    

 

 

 

Total assets

   $ 3,363,499       $ 3,203,824   
  

 

 

    

 

 

 

LIABILITIES AND EQUITY

     

Current portion of long-term debt

   $ 14,462       $ 14,416   

Other current liabilities

     418,900         386,762   
  

 

 

    

 

 

 

Total current liabilities

     433,362         401,178   
  

 

 

    

 

 

 

Long-term debt

     742,199         749,257   

Other noncurrent liabilities

     299,009         296,659   

Deferred income taxes

     81,555         77,903   

Albemarle Corporation shareholders’ equity

     1,722,937         1,591,277   

Noncontrolling interests

     84,437         87,550   
  

 

 

    

 

 

 

Total liabilities & equity

   $ 3,363,499       $ 3,203,824   
  

 

 

    

 

 

 

See accompanying notes to the condensed consolidated financial information.

 

6


Albemarle Corporation and Subsidiaries

Selected Consolidated Cash Flow Data

(In Thousands) (Unaudited)

 

     Three Months Ended
March 31,
 
     2012     2011  

Cash and cash equivalents at beginning of year

   $ 469,416      $ 529,650   

Cash and cash equivalents at end of period

   $ 519,359      $ 441,013   

Sources of cash and cash equivalents:

    

Net income

     112,414        113,767   

Proceeds from borrowings

     —          6,694   

Proceeds from exercise of stock options

     2,569        205   

Uses of cash and cash equivalents:

    

Capital expenditures

     (54,784     (31,894

Repayments of long-term debt

     (7,149     (100,622

Dividends paid to shareholders

     (15,578     (12,856

Pension and postretirement contributions

     (2,527     (51,949

Investments in equity and other corporate investments

     —          (10,666

Non-cash items:

    

Depreciation and amortization

     24,235        23,004   

Equity in net income of unconsolidated investments

     (8,586     (12,831

See accompanying notes to the condensed consolidated financial information.

 

7


Albemarle Corporation and Subsidiaries

Consolidated Summary of Segment Results

(In Thousands) (Unaudited)

 

     Three Months Ended  
     March 31,  
     2012     2011  

Net sales:

    

Polymer Solutions

   $ 228,131      $ 258,223   

Catalysts

     293,522        260,957   

Fine Chemistry

     190,051        177,350   
  

 

 

   

 

 

 

Total net sales

   $ 711,704      $ 696,530   
  

 

 

   

 

 

 

Segment operating profit:

    

Polymer Solutions

   $ 52,712      $ 69,831   

Catalysts

     75,415        62,131   

Fine Chemistry

     41,924        33,959   
  

 

 

   

 

 

 

Total segment operating profit

     170,051        165,921   
  

 

 

   

 

 

 

Equity in net income of unconsolidated investments:

    

Polymer Solutions

     1,845        2,489   

Catalysts

     6,741        10,461   

Fine Chemistry

     —          —     

Corporate & other

     —          (119
  

 

 

   

 

 

 

Total equity in net income of unconsolidated investments

     8,586        12,831   
  

 

 

   

 

 

 

Net income attributable to noncontrolling interests:

    

Polymer Solutions

     (1,002     (2,846

Catalysts

     —          —     

Fine Chemistry

     (3,372     (4,425

Corporate & other

     3        84   
  

 

 

   

 

 

 

Total net income attributable to noncontrolling interests

     (4,371     (7,187
  

 

 

   

 

 

 

Segment income:

    

Polymer Solutions

     53,555        69,474   

Catalysts

     82,156        72,592   

Fine Chemistry

     38,552        29,534   
  

 

 

   

 

 

 

Total segment income

     174,263        171,600   

Corporate & other

     (21,902     (23,594

Interest and financing expenses

     (8,734     (9,592

Other (expenses) income, net

     (118     338   

Income tax expense

     (35,466     (32,172
  

 

 

   

 

 

 

Net income attributable to Albemarle Corporation

   $ 108,043      $ 106,580   
  

 

 

   

 

 

 

See accompanying notes to the condensed consolidated financial information.

 

8


Notes to the Condensed Consolidated Financial Information

 

(a) The quarter ended March 31, 2012 includes a gain of $8.1 million ($5.1 million after tax, or 6 cents per share) resulting from proceeds received in connection with the settlement of litigation (net of related legal fees). The quarter ended March 31, 2012 also includes an $8 million charitable contribution ($5.1 million after tax, or 6 cents per share) to the Albemarle Foundation.

Additional Information

It should be noted that earnings, earnings per share and effective income tax rates which exclude special items, as well as presentations of segment operating profit, segment income, EBITDA, EBITDA excluding special items, EBITDA margin and EBITDA margin excluding special items are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance.

A description of other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Investors section of our website at www.albemarle.com, under “Non-GAAP Reconciliations” under “Financials.” Also, see attached for a supplemental reconciliation of our segment operating profit and segment income amounts to GAAP Operating profit and GAAP Net income attributable to Albemarle Corporation, respectively, as well as for a supplemental reconciliation of our GAAP Net income attributable to Albemarle Corporation to EBITDA.

 

9


ALBEMARLE CORPORATION AND SUBSIDIARIES

Non-GAAP Reconciliation

(In Thousands)

(Unaudited)

Our segment information includes measures we refer to as “segment operating profit,” “segment income,” “EBITDA” and “EBITDA excluding special items,” which are financial measures that are not required by, or presented in accordance with, GAAP. The Company reports segment operating profit, segment income, EBITDA and EBITDA excluding special items because management believes that these financial measures provide transparency to investors and enable period-to-period comparability of financial performance. Segment operating profit, segment income, EBITDA and EBITDA excluding special items should not be considered as alternatives to Operating profit or Net income attributable to Albemarle Corporation, as determined in accordance with GAAP.

See below for a reconciliation of segment operating profit and segment income, the non-GAAP financial measures, to Operating profit and Net income attributable to Albemarle Corporation, respectively, the most directly comparable financial measures calculated and reported in accordance with GAAP.

 

     Three Months Ended
March 31,
 
     2012     2011  

Total segment operating profit

   $ 170,051      $ 165,921   

Corporate & other *

     (21,905     (23,559
  

 

 

   

 

 

 

GAAP Operating profit

   $ 148,146      $ 142,362   
  

 

 

   

 

 

 

Total segment income

   $ 174,263      $ 171,600   

Corporate & other

     (21,902     (23,594

Interest and financing expenses

     (8,734     (9,592

Other (expenses) income, net

     (118     338   

Income tax expense

     (35,466     (32,172
  

 

 

   

 

 

 

GAAP Net income attributable to Albemarle Corporation

   $ 108,043      $ 106,580   
  

 

 

   

 

 

 

 

* Excludes corporate equity income and noncontrolling interest adjustments of $3 and $(35) for the three-month periods ended March 31, 2012 and 2011, respectively.

 

10


See below for a reconciliation of EBITDA, the non-GAAP financial measure, from Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. EBITDA is defined as Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, depreciation and amortization.

 

     Three Months Ended  
     March 31,  
     2012     2011  

Net income attributable to Albemarle Corporation

   $ 108,043      $ 106,580   
  

 

 

   

 

 

 

Add:

    

Interest and financing expenses

     8,734        9,592   

Income tax expense

     35,466        32,172   

Depreciation and amortization

     24,235        23,004   
  

 

 

   

 

 

 

EBITDA

     176,478        171,348   
  

 

 

   

 

 

 

Net Sales

   $ 711,704      $ 696,530   
  

 

 

   

 

 

 

EBITDA Margin

     24.8     24.6
  

 

 

   

 

 

 

 

11